Narazaciclib

N/A

Report date: 2026/01/16 10:34:19
NME

Base Information

Drug NameNarazaciclib
Drug Alias NameHX-301ON-123300
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsCyclin-dependent kinase 4 inhibitors +[5] 
TargetsCyclin-dependent kinase 6Colony stimulating factor 1 receptorTyrosine-protein kinase receptor FLT3 +[5] 
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsBreast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTemple University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTraws Pharma IncWuhan Hanxiong Biotechnology Co LtdHanx Biopharmaceutical Co Ltd
Inactive CompaniesIcahn School Of Medicine At Mount Sinai
Active IndicationsSolid tumoursEndometrial NeoplasmsBreast Neoplasms +[5] 
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksDrugBank